Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
December 03, 2021 10:01 ET
|
Neurona Therapeutics
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase...
Matt Tifft Joins Prestigious Forbes 30 Under 30 Class of 2022
December 03, 2021 09:00 ET
|
Live Fast Motorsports
MOORESVILLE, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Live Fast Motorsports co-owner Matt Tifft's career took a bit of a detour over the past few years, seeing the 25-year-old transition from the...
Rising Prevalence of Chronic Diseases Among People Across the Globe to Propel the Growth of the Global Neuromodulation Devices Market by 2026 – Exclusive Report [150 Pages] By Research Dive
December 01, 2021 09:00 ET
|
Research Dive
New York, USA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global neuromodulation devices market is expected to generate a revenue of $9,332.9 million,...
Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting
November 29, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET
|
Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
November 04, 2021 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders,...
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
November 04, 2021 07:00 ET
|
reMYND
Press Release reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company...
Researchers boost human mental function with brain stimulation
November 01, 2021 09:28 ET
|
University of Minnesota Medical School
MINNEAPOLIS/ST. PAUL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- In a pilot human study, researchers from the University of Minnesota Medical School and Massachusetts General Hospital show it is possible to...
Blood Brain Barrier Technologies Market Size ($5,101.94Mn by 2028) Lead by Neurological Disorders (25.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 21, 2021 11:42 ET
|
The Insight Partners
New York, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The new research study on the Blood Brain Barrier Technologies Market Size and Forecast to 2028 By Technology (Bispecific Antibody RMT Approach, Trojan...
Global Neuromodulation Devices Market to Undergo Significant Growth Due to Rising Adoption for Neuromodulation Devices in COVID-19 Pandemic – Exclusive Report [150 Pages] By Research Dive
August 25, 2021 09:02 ET
|
Research Dive
New York, USA, Aug. 25, 2021 (GLOBE NEWSWIRE) -- A latest report on the global neuromodulation devices market published by Research Dive sheds light on the impact of COVID-19 pandemic on the current...